Organon (OGN) Total Non-Current Liabilities (2020 - 2026)

Organon (OGN) recorded quarterly Total Non-Current Liabilities of $11.1 billion in Q1 2026, little changed quarter-over-quarter from $11.1 billion in Q4 2025, and down 4.4% on a YoY basis from $11.6 billion in Q1 2025.

Organon (OGN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Organon's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $11.1 billion for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities fell 4.4% year-over-year to $11.1 billion; the TTM figure through Mar 2026 stood at $11.1 billion (down 4.4% YoY), while the FY2025 annual figure was $11.1 billion, down 4.68% from the prior year.
  • Total Non-Current Liabilities was $11.1 billion for Q1 2026 at Organon, roughly flat from $11.1 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $11.7 billion in Q4 2023 to a low of $11.1 billion in Q3 2022.
  • Historically, Total Non-Current Liabilities has averaged $11.4 billion across 5 years, with a median of $11.4 billion in 2022.
  • Biggest YoY gain for Total Non-Current Liabilities was 270.75% in 2022; the steepest drop was 11.13% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $11.4 billion in 2022, then grew by 2.45% to $11.7 billion in 2023, then retreated by 0.55% to $11.7 billion in 2024, then fell by 4.68% to $11.1 billion in 2025, then climbed by 0.02% to $11.1 billion in 2026.
  • The last three Total Non-Current Liabilities figures came in at $11.1 billion (Q1 2026), $11.1 billion (Q4 2025), and $11.5 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Gsk 93,026,132.38 Bn 93,026,127.42 Bn 7.76 Bn -31.03 Bn
2 Eli Lilly 1,022.62 Bn 1,017.34 Bn 16.22 Bn 48.74 Bn
3 Johnson & Johnson 570.65 Bn 548.59 Bn 15.96 Bn 119.22 Bn
4 AbbVie 398.73 Bn 389.38 Bn 10.78 Bn 108.96 Bn
5 Merck 295.53 Bn 289.88 Bn 12.09 Bn 75.11 Bn
6 Amgen 186.30 Bn 174.26 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn 31.56 Bn
8 Pfizer 146.09 Bn 133.32 Bn -1.21 Bn 113.51 Bn
9 Bristol Myers Squibb 114.98 Bn 104.53 Bn 8.07 Bn 61.52 Bn
10 Organon 3.49 Bn 2.37 Bn 783.00 Mn 11.11 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 11.11 Bn
Dec 31, 2025 11.11 Bn
Sep 30, 2025 11.52 Bn
Jun 30, 2025 11.65 Bn
Mar 31, 2025 11.62 Bn
Dec 31, 2024 11.65 Bn
Sep 30, 2024 11.59 Bn
Jun 30, 2024 11.46 Bn
Mar 31, 2024 11.29 Bn
Dec 31, 2023 11.72 Bn
Sep 30, 2023 11.18 Bn
Jun 30, 2023 11.14 Bn
Mar 31, 2023 11.08 Bn
Dec 31, 2022 11.44 Bn
Sep 30, 2022 11.06 Bn
Jun 30, 2022 11.30 Bn
Mar 31, 2022 11.39 Bn
Dec 31, 2021 11.73 Bn
Sep 30, 2021 12.45 Bn
Jun 30, 2021 12.36 Bn